Circulating levels of soluble CD40L and coronary heart disease: three case-control studies

被引：0
|
作者：
Tavendale, R [1 ]
Chen, R [1 ]
Tunstall-Pedoe, H [1 ]
机构：
[1] Univ Dundee, Ninewells Hosp & Med Sch, Cardiovasc Epidemiol Unit, Dundee DD1 9SY, Scotland
来源：
EUROPEAN HEART JOURNAL | 2003年 / 24卷
关键词：
D O I：
10.1016/S0195-668X(03)95368-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：467 / 467
页数：1
相关论文
共 50 条
  • [31] Multilocus Heterozygosity and Coronary Heart Disease: Nested Case-Control Studies in Men and Women
    Mukamal, Kenneth J.
    Jensen, Majken K.
    Pers, Tune H.
    Pai, Jennifer K.
    Kraft, Peter
    Rimm, Eric B.
    PLOS ONE, 2015, 10 (05):
  • [32] Impact on fibrinogen and soluble CD40L of a single nucleotide polymorphism on interleukin 6 gene promoter in patients with stable coronary artery disease
    Hatzis, G.
    Tousoulis, D.
    Papageorgiou, N.
    Miliou, A.
    Antoniades, C.
    Maniatis, K.
    Bouras, G.
    Latsios, G.
    Siasos, G.
    Stefanadis, C.
    EUROPEAN HEART JOURNAL, 2011, 32 : 263 - 263
  • [33] Circulating soluble L-selectin levels in Kawasaki disease with coronary artery lesions
    Hirao, J
    Yamashita, T
    ACTA PAEDIATRICA JAPONICA, 1997, 39 (02): : 290 - 292
  • [34] Soluble CD40L in children and adolescents with type 1 diabetes: relation to microvascular complications and glycemic control
    El-Asrar, Mohamed A.
    Adly, Amira A. M.
    Ismail, Eman A.
    PEDIATRIC DIABETES, 2012, 13 (08) : 616 - 624
  • [35] ELEVATED PLASMA LEVELS OF SOLUBLE CD30 AND CD40L ARE ASSOCIATED WITH GRAFT DYSFUNCTION IN PEDIATRIC LIVER RECIPIENTS.
    Gautier, Sergey V.
    Tsirulnikova, Olga M.
    Gichkun, Olga E.
    Kurabekova, Rivada M.
    Ammosov, Alexander A.
    Shevchenko, Olga P.
    PEDIATRIC TRANSPLANTATION, 2011, 15 : 58 - 58
  • [36] Prospective study of circulating soluble CD40 ligand concentrations and the incidence of cardiovascular disease in a nested prospective case-control study of older men and women
    Jefferis, B. J.
    Whincup, P. H.
    Welsh, P.
    Wannamethee, S. G.
    Rumley, A.
    Lawlor, D. A.
    Ebrahim, S.
    Lowe, G. D. O.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (08) : 1452 - 1459
  • [37] Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients
    Malyszko, J
    Malyszko, JS
    Hryszko, T
    Mysliwiec, M
    BLOOD COAGULATION & FIBRINOLYSIS, 2004, 15 (06) : 463 - 467
  • [38] Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behcet disease patients
    Fernandez Bello, Ihosvany
    Alvarez, Maria T.
    Lopez-Longo, Francisco J.
    Arias-Salgado, Elena G.
    Martin, Monica
    Jimenez-Yuste, Victor
    Rodriguez de la Rua, Ana
    Butta, Nora V.
    THROMBOSIS AND HAEMOSTASIS, 2012, 107 (01) : 88 - 98
  • [39] Soluble CD40L versus myocyte enhancer factor: Predicting a prominent marker for cardiovascular disease.
    de Trad, Chafia Hejase
    2006 28th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Vols 1-15, 2006, : 1424 - 1427
  • [40] Could soluble levels of CD40L and galectin-9 be possible prognostic biomarkers and therapeutic targets in NSCLC?
    Costa, Guilherme Jorge
    da Matta, Marina Catena
    Torres, Leuridan Cavacante
    Casarini, Dulce Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345